Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2041
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2043.
US 11,312,704
Inhibitors of Cysteine Proteases and Methods of Use Thereof
no later than Apr 14, 2041
20262031203620412043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
6 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Apr 2041 · Medium confidence
Also notable
Ends May 2041 · High confidence
Also notable
Ends Jun 2043 · High confidence
Inhibitors of Cysteine Proteases and Methods of Use Thereof
US 11,312,704
Cited by 23 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2041. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Inhibitors of Cysteine Proteases and Methods of Use Thereof
US 11,174,231
Cited by 24 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2041.
Inhibitors of Cysteine Proteases and Methods of Use Thereof
US 12,747,230
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitors of Cysteine Proteases and Methods of Use Thereof (2021) | 3 in force | to May 2041 |
| Inhibitors of Cysteine Proteases and Methods of Use Thereof (2021) | 3 in force | to Apr 2041 |
| Inhibitors of Cysteine Proteases and Methods of Use Thereof (2021) | 1 in force | to Jun 2043 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,124,497 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,312,704 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,472,793 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,174,231 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,524,940 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,145,911 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,747,230 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 6 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed